U.S. markets open in 1 hour 7 minutes

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
167.52-2.27 (-1.34%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close169.79
Open169.00
Bid159.00 x 900
Ask171.00 x 800
Day's Range165.90 - 170.00
52 Week Range101.81 - 178.64
Volume553,009
Avg. Volume746,354
Market Cap9.436B
Beta (5Y Monthly)1.06
PE Ratio (TTM)39.70
EPS (TTM)4.22
Earnings DateMay 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est202.53
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
3% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering
    PR Newswire

    Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company" or "Jazz") today announced the pricing of the previously announced offering (the "Offering") of $1.5 billion in an aggregate principal amount of 4.375% senior secured notes due 2029 (the "Notes") by Jazz Securities Designated Activity Company, a direct wholly owned subsidiary of the Company (the "Issuer"). The Notes will mature on January 15, 2029 and will bear an interest rate of 4.375%. The Notes will be guaranteed by the Company and certain of its subsidiaries. The Offering is expected to close on April 29, 2021 subject to customary closing conditions.

  • JAZZ vs. ZTS: Which Stock Is the Better Value Option?
    Zacks

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

  • Moody's

    Jazz Securities Designated Activity Company -- Moody's assigns Ba2 to Jazz Pharma's secured notes; negative outlook

    Rating Action: Moody's assigns Ba2 to Jazz Pharma's secured notes; negative outlookGlobal Credit Research - 20 Apr 2021New York, April 20, 2021 -- Moody's Investors Service ("Moody's") assigned a Ba2 rating to the new senior secured notes issuance of Jazz Securities Designated Activity Company, a subsidiary of Jazz Pharmaceuticals plc (collectively "Jazz"). There are no changes to the existing ratings of the company, including the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, or the SGL-1 Speculative Grade Liquidity Rating. The outlook remains unchanged at negative.Proceeds of the notes, together with secured credit facilities, cash on hand, and equity will be used to fund the acquisition of GW Pharmaceuticals along with the various fees and expenses for approximately $6.7 billion net of cash acquired.Ratings assigned:..Jazz Securities Designated Activity Company:Guaranteed Senior secured notes, assigned Ba2 (LGD3)RATINGS RATIONALEJazz's Ba3 rating reflects the company's position as a specialized pharmaceutical company with approximately $2.9 billion of pro forma revenue including GW Pharmaceuticals.